<DOC>
	<DOCNO>NCT02155829</DOCNO>
	<brief_summary>The purpose study determine whether Riluzole effective augmentation treatment post-traumatic stress disorder ( PTSD ) experience Active Duty military service member Operation Enduring Freedom ( OEF ) , Operation Iraqi Freedom ( OIF ) , Operation New Dawn ( OND ) veterans symptom reduction one kinds medication therapy .</brief_summary>
	<brief_title>Safety Study Riluzole Treat Post-traumatic Stress Disorder ( PTSD )</brief_title>
	<detailed_description />
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>Activeduty service member Operation Iraqi Freedom ( OIF ) , Operation Enduring Freedom ( OEF ) , Operation New Dawn ( OND ) veteran . Clinical diagnosis PTSD achieve remission adequate trial medication treatment ( 8 week ) indicate selfreport referral confirm baseline CAPS score great = 40 inform consent obtain . 1 . Female subject childbearing capacity test positively ÃŸHCG , either selfreporting pregnant , plan become pregnant , nursing . 2 . Presence psychotic feature . 3 . Unable provide inform consent comply study procedure . 4 . Previous treatment riluzole . 5 . Serious , unstable illness include hepatic , renal , gastroenterological , respiratory , cardiovascular ( include ischemic heart disease ) , endocrinologic , neurologic , immunologic , hematologic disease , HIV . This include individual history COPD diagnosis well person take inhaler Asthma Reactive Airway Disease . 6 . Clinically significant abnormal level ( 3x ULN great ) serum transaminase ( ALT/SGPT ; AST/SGOT ) , current past blood dyscrasia . 7 . Subjects uncorrected hypothyroidism hyperthyroidism . 8 . DSMIV alcohol substance abuse dependence within 90 day screen visit . 9 . Treatment reversible MAOI , guanethidine , guanadrel within 1 week , change fluoxetine dosing within 8 week prior visit 2 . Use antidepressant sedative/hypnotic drug stable dose permit . 10 . Documented history hypersensitivity intolerance riluzole . 11 . Subjects current past history axis I disorder include schizophrenia , schizoaffective disorder , bipolar disorder dementia . However , comorbid history Axis I disorder like major depression , dysthymia anxiety disorder include ; justification approximately 70 % subject PTSD comorbid depression alcohol abuse , restrict sample PTSD patient without depression accurately reflect scope disorder . 12 . Patients currently high risk homicide suicide , indicate affirmative answer question : `` In last three month , attempt kill , make specific plan kill , intention kill ? '' 13 . Current planned litigation regard traumatic event . 14 . Patients recently start trauma focus cognitive behavioral psychotherapy ( Patient 's underlying educational supportive individual group therapy include ) . 15 . Patient 's actively enrol evidence base psychotherapy treatment ( e.g. , Cognitive Processing Therapy Prolonged Exposure Therapy ) exclude therapy conclude , may reapproached time patient selfreport clinician referral suggests persistent PTSD symptom upon conclusion treatment . 16 . Subjects artificial cardiac pacemaker metallic implant within body enrol WRNMMC placebocontrol clinical trial portion study . These individual , due preexist medical condition , medically ineligible participate 1H MRS image portion study . Further , Magnetic Resonance ( MRI ) Screening Form use WRNMMC use participant screen prior imaging procedure . 17 . Use benzodiazepine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>PTSD</keyword>
	<keyword>TBI</keyword>
	<keyword>Riluzole</keyword>
	<keyword>Rilutek</keyword>
	<keyword>augmentation</keyword>
	<keyword>supplement</keyword>
	<keyword>double blind</keyword>
	<keyword>clinical trial</keyword>
	<keyword>placebo</keyword>
	<keyword>RCT</keyword>
	<keyword>Randomized Control Trial</keyword>
</DOC>